ERBB2 and breast carcinoma: Several studies suggest that αvβ6 targeting may be an attractive therapeutic option; targeting αvβ6 in pre‐clinical breast cancer models using a monoclonal antibody, 264RAD, either alone or in combination with the HER2 inhibitor trastuzumab, resulted in significant inhibition of disease progression 9, 41.